Clinical trials: Psoriasis; Plaque
Plaque Psoriasis
Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis
This is a 16-week, prospective, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate psoriasis treated with ANM.
- Trial name
- NCT03817164
- Testing
- Autonomic Nerve Modulation - Active, Autonomic Nerve Modulation - Control
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Thync Global, Inc.
Psoriasis
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the…
- Trial name
- NCT01001208
- Testing
- Methotrexate, Etanercept
- Volunteers
- 478 people
- Sponsor
- Amgen
Moderate to Severe Plaque Psoriasis
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque…
- Trial name
- NCT06779097
- Testing
- Vunakizumab (IL-17A inhibitor)
- Where
- China
- Volunteers
- 1,564 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriasis
A Study for Adults With Plaque Psoriasis
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
- Trial name
- NCT01018810
- Testing
- LY2525623 Intravenous, LY2525623 Subcutaneous
- Where
- 28 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
- Trial name
- N/Z (NCT07489885)
- Testing
- D-2570 Tablet
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- InventisBio Co., Ltd
Plaque Psoriasis
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.
- Trial name
- NCT00540618
- Testing
- MEDI-507
- Where
- 43 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- MedImmune LLC
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma
Plaque Psoriasis
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
- Trial name
- Ixora-peds (NCT03073200)
- Testing
- Ixekizumab, Etanercept
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
- Trial name
- NCT00521339
- Testing
- Apremilast
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amgen
Psoriasis
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
- Trial name
- PROGRESS-RO (NCT07582783)
- Where
- 20 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to determine the superiority and efficacy of infliximab induction therapy in chinese participants with moderate to severe plaque-type psoriasis (scaly skin rash) compared with placebo (an inactive…
- Trial name
- NCT01177800
- Testing
- Infliximab
- Where
- 7 sites in China
- Volunteers
- 129 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Plaque Psoriasis
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
This multicenter, randomized, double-blind, active-controlled study aims to evaluate the efficacy and safety of picankibart in Chinese patients with plaque psoriasis who demonstrated inadequate responses to interleukin-17 (IL-17)…
- Trial name
- NCT06945107
- Testing
- Picankibart, Secukinumab, Ixekizumab
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Psoriasis
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645892
- Testing
- adalimumab
- Volunteers
- 32 people
- Sponsor
- Abbott
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
- Trial name
- IMMprint (NCT04713592)
- Testing
- Risankizumab
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 174 people
- Sponsor
- AbbVie
Psoriasis
A 36-Week Extension to Protocol ISA04-03
The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.
- Trial name
- SPIRIT (NCT00258713)
- Testing
- voclosporin
- Where
- 29 sites in Canada
- Volunteers
- 309 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Psoriasis
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT05645627
- Testing
- IBI112
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.